Abstract：Abstract: Cytokine induced killer (CIK) cells are heterogeneous population generated by in vitro expansion of mononuclear cells from peripheral blood, bone marrow or cord blood using IFN-γ, IL-2 and anti-CD3 antibodies. CIK cells possess an improved proliferation rate, potent cytotoxic activities against a wide spectrum of tumor cells including as well as charateries of T lymphocytes and non-major histocompatibility complex (non-MHC) restricted of NK cells. CIK cell-based immunotherapy is a promising new treatment option in cancer therapy. In recent reports, the patients with CIK cells adoptive immunotherapy for treating hematological malignant tumor achieve good improvement, but there are still many problems.
引用本文:
王艳飞, 杨, 丹, 杨同华, 撒亚莲. 细胞因子诱导杀伤细胞过继免疫治疗恶性血液肿瘤的临床应用进展[J]. 生命科学研究, 2015, 19(5): 465-470. WANG Yan-Fei, YANG , DAN , YANG Tong-Hua, SA Ya-Lian. Progresses on Clinical Trials Applying Cytokine Induce Killers Cells Adoptive Immunotherapy for Hematological Malignant Tumor. Life Science Research, 2015, 19(5): 465-470.
2015,Vol. 19
